1.56MMarket Cap-51P/E (TTM)
0.7689High0.6316Low271.54KVolume0.7673Open0.7731Pre Close190.62KTurnover15.04%Turnover RatioLossP/E (Static)2.11MShares11.774052wk High-1.28P/B1.34MFloat Cap0.631652wk Low--Dividend TTM1.81MShs Float360.0000Historical High--Div YieldTTM17.76%Amplitude0.6310Historical Low0.7020Avg Price1Lot Size
Virpax Pharmaceuticals Stock Forum
Virpax Pharmaceuticals Inc - Liposomal Formulation Developed to Provide Both Immediate and Sustained Pain Relief
NEWS
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Virpax Pharmaceuticals, Inc. announced the results of a Maximum Tolerated Dose (MTD) study for Probudur™, a long-acting liposomal bupivacaine formulation aimed at reducing the need for opioids after surgery. The study showed that Probudur provided both immediate and sustained pain relief at the wound site, with minimal toxicity and better therapeutic results compared to free bupivacaine....
no news
No comment yet